ReviewFrontiers in pharmacology2026
The effects of traditional Chinese botanical medicine on membranous nephropathy.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Membranous nephropathy (MN), an autoimmune glomerulopathy driven by podocyte antigens, is a leading cause of end-stage renal disease (ESRD). However, its pathogenic mechanisms remain incompletely understood. This knowledge gap results in significant physical and psychological burdens for patients worldwide and poses substantial challenges for clinical management. Current conventional treatments for MN are often associated with significant side effects and may not yield satisfactory outcomes. Therefore, the development of more efficacious and better-tolerated therapeutic strategies for MN is imperative. Given these clinical challenges, Traditional Chinese Botanical Medicine (CHMs), with their multi-component and multi-target characteristics, have emerged as a promising alternative or complementary therapeutic approach for MN. This review aims to summarize the evidence on the mechanisms and clinical efficacy of CHMs and their active metabolites in treating MN, drawing from findings reported in animal experiments, clinical trials, systematic reviews, and meta-analyses. It seeks to elucidate the potential advantages of CHMs in MN management and to provide a reference for future research in this field. Study design and methods: For this review, the following major academic research databases were consulted: PubMed, ResearchGate, Science Direct, and Web of Science. "Glomerulonephritis, Membranous [MeSH Terms] OR Extramembranous Glomerulopathy [Text Word] OR Membranous Glomerulonephropathy [Text word] OR Membranous Nephropathy [Text word] OR Idiopathic Membranous Glomerulonephritis [Text word]OR Glomerulonephritides, Idiopathic Membranous. [Text word])," "(Medicine, Chinese Traditional [MeSH Terms] OR Medicine, Chinese Traditional [Text Word] OR Medicine, Chinese Traditional [Text word] OR Tongue Diagnosis, Traditional [Text word] OR Traditional Tongue Assessment [Text word]," "Drugs, Chinese Herbal [MeSH Terms] OR Chinese Drugs, Plant [Text Word] OR Chinese Herbal Drugs [Text word] OR Plant Extracts, Chinese [Text word] OR Chinese Plant Extracts [Text word]," "mechanism," "Meta-analysis," "systematic review," "RCT," "botanical drug" and their combinations were the keywords to search the relevant literature. Data were collected from 2019 to 2025.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.